Vex

Immunohistochemical analysis conditions. (PDF 273 kb

Comparison of predictive accuracy achieved in breast cancer through differing prognostic methodologies (N = 1,225).

<p>Note: T values and accompanying 2-tail P values refer to reductions in mean absolute probabilistic error achieved relative to the prognostic methodology tabled in the line immediately above, where each matched-pair T test is applied to the indicated 1,225 matched pairs of individual probabilistic prediction errors.</p

Kaplan-Meier analysis of DSS of high-risk patients identified by traditional eligibility for high-dose IFN only (curve 1), those identified by both criteria (curve 2), and those identified by the tailored prognostic model only (curve 3).

<p>Kaplan-Meier analysis of DSS of high-risk patients identified by traditional eligibility for high-dose IFN only (curve 1), those identified by both criteria (curve 2), and those identified by the tailored prognostic model only (curve 3).</p

Panel A. Kaplan-Meier analysis of DSS by prognostic subgroup in the melanoma cohort.

<p>Panel B. Kaplan-Meier analysis of DSS by prognostic subgroup in the breast cancer cohort.</p

Panel A. ROC plots of 5-year melanoma-specific death probabilities estimated by different logistic regression analyses.

<p>Panel B. ROC plots of 5-year breast cancer-specific death probabilities estimated by different logistic regression analyses. In each panel, curve 1 represents the ROC plot using initial AJCC stage (unstratified), curve 2 the ROC plot stratified by AJCC stage, and curve 3 the ROC plot determined by the composite weighted index.</p

Comparison of predictive accuracy achieved in melanoma through differing prognostic methodologies (N = 1,222).

<p>Note: T values and accompanying 2-tail P values refer to reductions in mean absolute probabilistic error achieved relative to the prognostic methodology tabled in the line immediately above, where each matched-pair T test is applied to the indicated 1,222 matched pairs of individual probabilistic prediction errors.</p

Supplementary Data 1 from Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinoma

Supplementary Data 1 from Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinom

Supplementary Data 3 from Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinoma

Supplementary Data 3 from Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinom

Supplementary Data 2 from Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinoma

Supplementary Data 2 from Merkel Cell Polyomavirus Infection, Large T Antigen, Retinoblastoma Protein and Outcome in Merkel Cell Carcinom

Additional file 1: of Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

Figure S1. Immuno-electron microscopy images showing (A) FBS exosomes treated with T-DM1, and (B) SNU-216 exosomes treated with PBS (Type A exosomes). No T-DM1 is detectable on the exosomes. (TIF 1108 kb